Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
9. lappuse
... tion , even though such combination containing such substance in other pro- portion is not a new drug . ( 4 ) The newness of use of such drug in diagnosing , curing , mitigating , treat- ing , or preventing a disease , or to af- fect a ...
... tion , even though such combination containing such substance in other pro- portion is not a new drug . ( 4 ) The newness of use of such drug in diagnosing , curing , mitigating , treat- ing , or preventing a disease , or to af- fect a ...
11. lappuse
... tion at the address shown in paragraph ( e ) of this section . ( e ) Interested parties may submit to the Food and Drug Administration , Center for Drug Evaluation and Re- search , Office of Compliance , HFD - 300 , 5600 Fishers Lane ...
... tion at the address shown in paragraph ( e ) of this section . ( e ) Interested parties may submit to the Food and Drug Administration , Center for Drug Evaluation and Re- search , Office of Compliance , HFD - 300 , 5600 Fishers Lane ...
13. lappuse
... tion . ( d ) Prescription legend not allowed on exempted drugs . The use of the prescrip- tion caution statement quoted in sec- tion 503 ( b ) ( 4 ) of the act , in the labeling of a drug exempted under the provi- sions of this section ...
... tion . ( d ) Prescription legend not allowed on exempted drugs . The use of the prescrip- tion caution statement quoted in sec- tion 503 ( b ) ( 4 ) of the act , in the labeling of a drug exempted under the provi- sions of this section ...
15. lappuse
... tion with the dosage recommendations : ( a ) Clear warning statements against administration of the drug to children under 6 years of age , except as directed by a physician , and against driving a car or operating machinery while using ...
... tion with the dosage recommendations : ( a ) Clear warning statements against administration of the drug to children under 6 years of age , except as directed by a physician , and against driving a car or operating machinery while using ...
16. lappuse
... tion by external application to the skin , and containing no drug limited to prescription sale under the provisions of section 503 ( b ) ( 1 ) of the act . ( ii ) The sulfur dioxide and all other components of the preparation meet their ...
... tion by external application to the skin , and containing no drug limited to prescription sale under the provisions of section 503 ( b ) ( 1 ) of the act . ( ii ) The sulfur dioxide and all other components of the preparation meet their ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning